Cagrilintide 10mg

Cagrilintide is a long-acting amylin analogue developed to investigate the role of amylin receptor activation in appetite regulation, satiety, and body weight management. It is designed for once-weekly administration due to structural modifications that extend its half-life compared with native amylin.

Originally developed by Novo Nordisk, cagrilintide has been studied both as a standalone investigational compound and in combination with semaglutide (often referred to in research as CagriSema) for potential weight management applications.

Origin

Amylin is a naturally occurring peptide hormone that is co-secreted with insulin by the pancreas after meals. Its physiological role includes:

Promoting feelings of fullness (satiety)

Slowing gastric emptying

Reducing food intake

Helping regulate post-meal glucose responses

Native human amylin has a very short half-life, limiting its therapeutic usefulness. Cagrilintide was engineered as a long-acting analogue to provide sustained receptor activation with convenient once-weekly dosing in clinical research.

Mechanism of Action

Cagrilintide acts by activating amylin receptors located in regions of the brain involved in appetite regulation. Activation of these receptors may:

Increase satiety

Reduce hunger signals

Decrease caloric intake

Slow gastric emptying

Influence body weight through reduced food consumption

Unlike GLP-1 receptor agonists, cagrilintide works through the amylin pathway, making it a distinct investigational compound with complementary mechanisms.

Areas of Research

Current clinical and preclinical research has investigated cagrilintide for:

Body weight regulation

Appetite and satiety mechanisms

Obesity research

Metabolic health

Combination therapy with GLP-1 receptor agonists

Long-term energy balance

Potential Benefits Observed in Research

Research studies have reported that cagrilintide may:

Promote prolonged feelings of fullness

Reduce overall food intake

Support significant reductions in body weight

Complement GLP-1 receptor agonists through a different biological pathway

Provide once-weekly activity because of its extended duration

The degree of these effects has varied depending on study design, participant characteristics, and whether cagrilintide was used alone or in combination with other investigational therapies.

Pharmacological Characteristics

Compound Type: Long-acting amylin analogue

Administration: Investigated primarily as a once-weekly subcutaneous injection

Research Focus: Appetite regulation and body weight management

Target: Amylin receptors

Status: Investigational compound

Storage

For research purposes, lyophilized material is generally stored refrigerated or frozen according to the manufacturer’s specifications. Once reconstituted, storage conditions should follow laboratory protocols and supplier recommendations to preserve stability.

Research Disclaimer

This compound is intended for laboratory and scientific research purposes only. It is not approved for general clinical use as a standalone medicine in many jurisdictions, and its safety and efficacy continue to be evaluated through ongoing research. It is not intended to diagnose, treat, cure, or prevent any disease outside approved regulatory indications where applicable.